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Abstract
Background: Autotaxin (ATX, NPP-2), originally purified as a potent tumor cell motility factor,
is now known to be the long-sought plasma lysophospholipase D (LPLD). The integrity of the
enzymatic active site, including three crucial histidine moieties, is required for motility stimulation,
as well as LPLD and 5'nucleotide phosphodiesterase (PDE) activities. Except for relatively non-
specific chelation agents, there are no known inhibitors of the ATX LPLD activity.
Results: We show that millimolar concentrations of L-histidine inhibit ATX-stimulated but not
LPA-stimulated motility in two tumor cell lines, as well as inhibiting enzymatic activities. Inhibition
is reversed by 20-fold lower concentrations of zinc salt. L-histidine has no significant effect on the
Km of LPLD, but reduces the Vmax by greater than 50%, acting as a non-competitive inhibitor.
Several histidine analogs also inhibit the LPLD activity of ATX; however, none has greater potency
than L-histidine and all decrease cell viability or adhesion.
Conclusion: L-histidine inhibition of LPLD is not a simple stoichiometric chelation of metal ions
but is more likely a complex interaction with a variety of moieties, including the metal cation, at or
near the active site. The inhibitory effect of L-histidine requires all three major functional groups
of histidine: the alpha amino group, the alpha carboxyl group, and the metal-binding imidazole side
chain. Because of LPA's involvement in pathological processes, regulation of its formation by ATX
may give insight into possible novel therapeutic approaches.
Background
Lysophosphosphatidic acid (LPA) is both an intracellular
and an extracellular signaling molecule that affects biolog-
ical processes such as cell proliferation, rescue from apop-
tosis, cell migration, neurite retraction, wound healing,
platelet aggregation and vascular remodeling [1]. As a
cytokine affecting such varied and important functions,
LPA production is normally tightly regulated. Its dysregu-
lation is implicated in a number of pathophysiological
states, including certain cancers and atherogenesis. Intrac-
ellularly, LPA is produced by calcium-dependent and cal-
cium-independent phospholipase A2, acting on
phosphatidic acid. Most of the extracellular LPA appears
to be produced by a two-step process: production of
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phospholipase A1 or A2, followed by conversion to LPA
by the plasma enzyme lysophospholipase D (LPLD) [2,3].
Recently, this plasma LPLD has been shown to be identi-
cal to autotaxin (ATX, NPP2) [4,5].
ATX was originally purified as a potent tumor cell moto-
gen [6], an effect that appears to be mediated by LPA [7]
acting through the LPA1 receptor [8]. Recent studies have
revealed that ATX/LPLD not only hydrolyzes lyso-phos-
phoglycerolipids to form LPA, but also hydrolyzes sphin-
gosylphoshorylcholine (SPC) to produce sphingosine-1-
phosphate (S1P) [9]. S1P can stimulate or inhibit cellular
migration, depending upon the context of receptor
expression [10]. Therefore, ATX can produce either ago-
nists or antagonists of cell migration. In addition, ATX has
been shown to stimulate tumor aggressiveness and to be
over-expressed in certain malignancies [11-13]. The link
between ATX and its putative 'mediator' LPA has led us to
investigate possible mechanisms of regulating the enzy-
matic action of ATX in generating LPA.
ATX is a member of the nucleotide pyrophosphatase and
phosphodiesterase (NPP) family of enzymes. The NPPs
are part of the superfamily of alkaline phosphatases, met-
alloenzymes in which the active site is characterized by
histidine residues coordinated around central divalent
cations and by a serine, threonine, or cysteine residue,
which is utilized to form an intermediate during the reac-
tion [14,15]. Site-directed mutagenesis of human ATX
established that a specific residue, T210, [7,16] and 3 his-
tidine residues [7,9], corresponding to similar loci in
other members of the alkaline phosphatase superfamily,
were essential for the motility and enzymatic activities of
ATX.
Histidine has been implicated as a requirement for many
metalloenzymatic reactions, presumably by virtue of its
imidazole moiety. Reversible reagents such as diethylpy-
rocarbonate, which react with imidazole, inhibit these
enzymes [17]. Such findings led us to investigate whether
histidine itself and some of its derivatives could inhibit
the activities of ATX, perhaps by destabilizing the putative
metallic cation-imidazole complex at the active site of
ATX. Since the migratory effects of ATX depend upon its
ability to generate LPA or S1P, focusing upon ATX as a tar-
get for regulation of tumor cell motility presents an attrac-
tive strategy for therapeutic intervention in metastasis.
Results
Effect of L-Histidine upon Cell Motility
ATX, isolated as a motility-stimulating protein, is a mem-
ber of the NPP family of metalloenzymes. Both its moto-
genic and its enzymatic activities appear to require the
same active site since both are abolished when T210 [16]
or any of three histidines (H316, H360 or H476) are
altered by site-directed mutagenesis [7]. Because of the
crucial role that these histidines play in the ATX activities,
we tested the effect of adding exogenous L-histidine upon
ATX-stimulated cell motility.
Fig. 1 shows that L-histidine inhibited ATX-stimulated
migration of both A2058 human melanoma cells and
SKOV-3 human ovarian carcinoma cells in a concentra-
tion-dependent manner. Addition of 10 mM L-histidine
to motility assays resulted in a 90 – 95% reduction in
stimulated motility, whereas equivalent concentrations of
control amino acids, glycine or alanine (data not shown),
had no effect. In contrast, adding the same concentration
of L-histidine failed to inhibit LPA-stimulated motility.
These concentrations of L-histidine did not affect cell via-
bility in either cell line, as measured by Trypan Blue exclu-
sion. Whether the inhibitor was added to both wells of the
assay (i.e. to cells and to chemoattractant) or just to the
lower well (chemoattractant) did not affect the result.
ATX was pre-incubated with 200 nM LPC with or without
addition of various concentrations of L-histidine, then
heated to abolish its enzymatic activity [9] and added to
the bottom chamber of motility assays utilizing A2058
cells as responders. As seen in Fig. 2A, addition of L-histi-
dine to the pre-incubation mixture resulted in a 75% inhi-
bition of motility for A2058 cells at concentrations similar
to those utilized in Fig. 1. These data, which were identical
in SKOV-3 cells (data not shown), suggest that the L-histi-
dine acts upon the ATX-catalyzed LPLD reaction to pro-
duce its inhibitory effect by preventing the formation of
LPA from LPC. Previously, we have shown that SPC is an
alternate substrate for ATX: pre-incubation of SPC with
ATX, followed by heat-inactivation of ATX, resulted in
production of the inhibitor of LPA-stimulated A2058 cell
motility, S1P [9]. As seen in Fig 2B, inclusion of 20 mM L-
histidine in the ATX + SPC pre-incubation step prevented
the formation of an inhibitor of A2058 cell motility. L-his-
tidine therefore appears to inhibit the hydrolysis of both
glycerophospholipids and phosphosphingolipids.
Effects of Histidine and Metal ions upon ATX Activities
The PDE activity of the NPPs has been shown to be
dependent upon the presence of metal ions [15]. Toku-
mura and co-workers [18] demonstrated a similar require-
ment for a metal cation in the action of LPLD. Both Co++
and Zn++ were markedly effective in restoring enzymatic
activity to LPLD in EDTA-treated plasma. In fact, addition
of Co++ to EDTA-treated heparinized plasma resulted in a
recovery from 37% of the untreated value in the presence
of EDTA alone to 154% in the presence of Co++ and EDTA.
Since histidine plays an important structural role in the
catalytic process, we determined first that addition of free
histidine has an inhibitory effect upon ATX-catalyzedPage 2 of 13
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strates. After establishing the concentration requirements
for histidine inhibition, we next examined the capacity of
different metal cations to reverse this inhibition. Finally,
we determined how histidine and metal cations affect the
kinetics of the LPLD reaction.
As seen in Fig. 3A, histidine inhibited both LPLD (with
LPC as substrate) and PDE (with p-Nitrophenyl-TMP or
pNp-TMP as substrate) activities of ATX in a dose depend-
ent manner. At a concentration of 20 mM, this inhibition
was virtually complete for both reactions. The normalized
curves coincided closely with each other and the IC50 val-
ues (4.0 ± 1.1 mM and 4.5 ± 1.1 mM for LPLD and PDE
activities, respectively) were not significantly different
from each other.
We tested the effects of a number of divalent cations in
both the presence and absence of histidine upon the PDE
and LPLD activities of ATX (Fig. 3B). Neither Mg++ nor
Ca++ significantly reversed the inhibitory effect of histi-
dine although Ca++ alone enhanced both reactions by at
least 30%. However, Zn++ and Co++ each significantly
overcame inhibition caused by free histidine. In the case
of Zn++, the presence of the cation alone increased both
reactions by up to 50% above control, and virtually abol-
ished the inhibition caused by histidine, with recoveries
of 90 – 100% of the activity measured in the presence of
Zn++ alone. In the case of Co++, the cation alone increased
the PDE activity by 50% and the LPLD activity by 300%;
however, histidine still inhibited PDE by ~70% and LPLD
by 50% compared to adding Co++ alone. Zn++, therefore,
appears to be the most effective cation in reversing the
inhibition by histidine. It should also be noted that none
of the cations at the levels tested had any inhibitory effects
upon the enzymatic reactions of ATX. Histidine therefore
inhibits a process that is required for the hydrolysis of
Effect of histidine on ATX-stimulated motilityFigure 1
Effect of histidine on ATX-stimulated motility. The modified Boyden chamber motility assays are described in Materials 
and Methods. L-Histidine inhibits the motility response of A2058 and SKOV-3 cells to ATX but not to LPA (concentrations 
shown). All data are shown as Mean ± SEM. Means were analyzed utilizing the ANOVA/Tukey's post-test (GraphPad Prism, San 
Diego, CA): * (p < 0.001) for histidine-treated vs. untreated controls.Page 3 of 13
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Histidine appears to act by inhibiting the ATX LPLD activity. The modified Boyden chamber motility assays with 
A2058 cells are described in Materials and Methods. In these assays, pre-incubations were in DBA media for 3 hr at 37°C. A) 
L-histidine decreases formation of a chemoattractant by ATX. Shown concentrations of L-histidine were pre-incu-
bated with ATX plus 200 nM LPC, then ATX was heat-inactivated prior to utilizing the resulting mixture as chemoattractant in 
a motility assay (solid black bars). Data are compared to identical treatments of 100 nM LPA as chemoattractant (white bars). 
B.) L-histidine decreases formation of a motility inhibitor by ATX. Shown concentrations of L-histidine were pre-
incubated with (ATX + 100 nM SPC + 100 nM LPA). ATX was heat inactivated prior to utilizing the mixture as chemoattract-
ant. Controls are shown for comparison: DBA, 100 nM LPA, (100 nM LPA + 100 nM S1P), (100 nM LPA + 100 nM SPC). All 
data are shown as Mean ± SEM. Means were analyzed utilizing the ANOVA/Tukey's post-test (GraphPad Prism, San Diego, 
CA): * (p < 0.001) for histidine-treated vs. the appropriate untreated control.Page 4 of 13
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Histidine inhibition of ATX enzyme activities and sensitivity to zinc. For these reactions, 1 mM LPC served as sub-
strate for LPLD activity and 1 mM pNp-TMP as substrate for 5'-nucleotide PDE activity; approximately 6 pmoles of ATX was 
added to each reaction. A.) Product was measured in the presence of variable concentrations of L-histidine. Data are shown as 
Mean ± SEM. The two reactions were not significantly different from each other. B.) Different metal cations (0.5 mM) were 
compared for their capacity to abrogate L-histidine (10 mM) inhibition of enzymatic reactions. C.) Effect of Zn++ on LPC- and 
ATX-stimulated motility. Utilizing A2058 cells as responders and either ATX or 25 nM LPA as chemoattractant, 20 mM histi-
dine or 0.25 mM ZnSO4 or both were added to the bottom wells throughout the motility assay. Data are shown as Mean ± 
SEM. Means were compared with ANOVA/Tukey's post-test (GraphPad Prism, San Diego, CA). For B), comparisons were 
between histidine-treated vs. the equivalent untreated reactions with * (p < 0.001). For C), comparisons were as follows: * (p 
< 0.001) vs. ATX alone, ** (p < 0.001) vs. ATX + His, # (p < 0.01) vs. ATX alone.Page 5 of 13
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limiting cation-dependent step in their common reaction
mechanism [7].
Since Zn++ reversed the inhibitory effect of histidine upon
ATX enzymatic reactions, we tested its effect upon the his-
tidine-induced inhibition of ATX- and LPA-stimulated
motility. As shown in Fig. 3C for A2058 cells, 20 mM his-
tidine, 0.25 mM Zn++, or both together had no effect upon
LPA-induced motility. In contrast, ATX-induced motility
was affected in a more complex manner. Histidine (20
mM) alone inhibited ATX-induced motility by ~65%,
while 0.25 mM Zn++ alone increased this same motility by
~30%. When these same concentrations of histidine and
zinc were added together to an ATX-stimulated motility
assay, the histidine inhibition was largely reversed with
greater motility than seen with ATX alone, though not
quite up to levels seen with ATX + Zn++. However, statisti-
cal analysis of these results revealed no statistically signif-
icant difference between ATX + Zn++ + histidine vs. ATX +
Zn++. In contrast, there was a statistical significance
between ATX + Zn++ + histidine vs. ATX + histidine (p <
0.001).
Fig. 4 shows a concentration curve of the ATX-catalyzed
LPLD reaction with LPC as substrate, both with and with-
out addition of 10 mM histidine. The two reactions had
Km values (0.49 ± 0.05 mM untreated vs. 0.66 ± 0.18 mM
with histidine) that were not significantly different from
each other; however, Vmax was reduced more than 50%
by the addition of histidine. Also shown are the effects of
0.25 mM Zn++, alone or in addition to histidine. Zn++
alone had no significant effect on the Vmax or Km of the
reaction. In the presence of histidine, Zn++ reversed the
inhibition, restoring Vmax to untreated levels. It might be
noted that the pattern of inhibition seen when histidine is
added is typical of a non-competitive inhibitor.
Effect of Chelating Agents upon the ATX-stimulated 
Reaction
Because the histidine-induced inhibition of ATX activities
could be reversed by addition of appropriate metal ions
(i.e., Zn++), the possibility arose that the imidazole ring of
histidine acts as a weak chelation agent, competing with
the enzymatic active site for binding to the metal ion.
EDTA has been shown to inhibit the nucleotide phos-
phodiesterase and pyrophosphatase activities of PC-1/
NPP1 [19]. We, therefore, utilized EDTA, as well as the
metal chelating agent 1,10-phenanthroline, in order to
examine their effect upon the LPLD and PDE activities of
ATX. We also tested the reversibility of their effects with
Ca++ and with Zn++.
In a series of preliminary experiments (data not shown),
we found that, under the conditions of our enzymatic
assays, addition of 10 – 20 mM Na4-EDTA resulted in
profound inhibition of both LPLD and PDE activities with
an IC50 of approximately 5 mM. We also found that 5
mM Na4-EDTA required very nearly equimolar concentra-
tions of metal cations to reverse its inhibitory effects. As
shown in Fig. 5, addition of equimolar concentration of
Zn++ resulted in essentially complete recovery of activity
(range 90 – 110% recovery) for both LPLD and PDE activ-
ities, while an equimolar concentration of Ca++ resulted in
~75% recovery of control activity.
Addition of 0.5 mM 1,10-phenanthroline also profoundly
inhibited the LPLD activity of ATX (Fig. 5). The IC50 for
1,10-phenanthroline in this reaction was approximately
0.25 mM (data not shown). As has been reported previ-
ously, a significant recovery from 1,10-phenanthroline-
induced inhibition requires less than equimolar concen-
trations of Zn++ [20]. Addition of 0.05 mM Zn++ resulted
in a 70 – 80% recovery compared to control values, while
adding up to 5 mM Ca++ had no significant effect upon
phenanthroline-induced inhibition of activity. As can be
seen in Fig. 5, the pattern of recovery from 1,10-phenan-
throline-induced inhibition is similar to the pattern seen
with histidine-induced inhibition of LPLD.
Testing the effect of these chelating agents on motility was
problematic because chelation agents have multiple, com-
plex effects upon living cells. For example, Na4-EDTA
treatment killed our responder cells (A2058) in about 15
– 20 min, and 1,10-phenanthroline inhibited cellular
adhesion at concentrations utilized for inhibition of LPLD
and PDE activity. Therefore, we were unable to obtain
motility data in the presence of these agents.
Effects of Histidine Analogs upon the LPLD Reactivity of 
ATX
A number of histidine-derived agents, as well as histamine
and imidazole (Fig. 6A), were tested for their effects upon
the LPLD activity of ATX. Since 15 – 20 mM L-histidine
gave similar levels of inhibition, all reactions were carried
out in the presence of 15 mM inhibitor.
As seen in Fig. 6B, D-histidine and L-histidine are the most
effective inhibitors of the ATX LPLD activity, resulting in
approximately 75% reduction. They were not statistically
significant from each other. Nearly as inhibitory was his-
tidine methyl ester, which has an esterified alpha carboxyl
group and which reduced LPLD activity by 65%. Other
compounds with substitutions on the alpha carboxyl
group, histidinamide and histidinol, were markedly less
effective as inhibitors. Histidinol, in which the carboxyl
group is reduced to a hydroxy-methyl group, was not sta-
tistically different from untreated control reactions. His-
tidinamide, with amidylation of the alpha carboxyl
group, was mildly inhibitory, reducing activity ~20%. InPage 6 of 13
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Reaction rate vs. substrate concentration curves in the presence of L-histidine or zinc LPLD determinations were 
carried out in the presence of 10 mM L-histidine or 0.25 mM Zn++, as indicated. Curves were analyzed with GraphPad Prism 
(San Diego, CA) to calculate Km and Vmax, as shown.Page 7 of 13
(page number not for citation purposes)
Lipids in Health and Disease 2005, 4:5 http://www.lipidworld.com/content/4/1/5contrast, histamine, which lacks the alpha carboxyl group,
altogether, was slightly stimulatory to LPLD activity.
Histidine analogs with methyl groups added to the alpha
nitrogen were also less active than histidine itself. N, N-
dimethyl histidine was not statistically different from
untreated control, while N-methyl histidine, resulted in
just a 30% reduction in LPLD activity. Surprisingly, at the
tested concentrations, the metal-binding agent imidazole
had no effect on the LPLD activity of autotaxin. Likewise,
amino acids that resemble histidine without its imidazole
ring (e.g., glycine and L-alanine) also lack inhibitory activ-
ity (data not shown).
Among the five histidine analogs found to inhibit ATX
LPLD activity, the relative inhibitory activity is: D-histi-
dine = L-histidine > histidine methyl ester >> N-methyl
histidine > histidinamide. The effects of all of these agents
are reversed by zinc. In contrast, glycine, L-alanine, imida-
zole, histidinol, and N, N-dimethyl histidine had no sig-
nificant effect on activity; and histamine appeared to be
slightly stimulatory. Most of these histidine analogs,
including D-histidine, histidine methyl ester, histidina-
mide, N, N-dimethyl histidine, and histamine, were toxic
to cells. N-methyl histidine resulted in reduced adhesion
to our gelatin-coated membranes, precluding an effective
motility assay. Only imidazole could easily be tested for
its effect on ATX-stimulated motility. At 10–20 mM
concentrations, imidazole had no significant effect on
ATX-stimulated motility (data not shown).
Discussion
We have shown that L-histidine, at concentrations that are
innocuous to cells, can inhibit the motility-stimulating
action of ATX upon two tumor cell lines derived from
human melanoma (A2058) and human ovarian carci-
noma (SKOV-3). This inhibition is largely abrogated by
addition of 0.25 mM Zn++ to the motility assays. Pre-incu-
bation of ATX and LPC in the presence of L-histidine, fol-
Effect of chelating agents on ATX's LPLD activityFigure 5
Effect of chelating agents on ATX's LPLD activity The LPLD activity of ATX was compared in the presence of 0.5 mM 
phenanthroline A (phenA), 5 mM EDTA, or 10 mM L-histidine. The effect of adding Zn++ or Ca++ was compared for each 
chelating agent. Results are expressed as Mean ± SEM. Statistical analysis of results was performed utilizing GraphPad Prism 
(San Diego, CA). Data that is significantly different from untreated control is shown by: * (p < 0.001), ** (p < 0.05); recovery 
with metal cations is shown as statistically different from appropriate inhibitor-treated samples: # (p < 0.001).Page 8 of 13
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Effect of histidine analogs on LPLD activity A.) Chemical structure of histidine analogs compared. B.) Histidine analogs 
(15 mM) were added to the LPLD assay and analyzed for their effect on LPLD activity with (white bars) or without (black bars) 
addition of 1.0 mM Zn++. Results are shown as Mean ± SEM. Means, for each histidine analog vs. appropriate untreated control, 
were analyzed utilizing ANOVA/Tukey's post-test (GraphPad Prism, San Diego, CA): * (p < 0.001), ** (p < 0.01).Page 9 of 13
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decreased activity, suggesting that L-histidine inhibits
ATX-stimulated motility by ablating its LPLD activity. This
hypothesis was in fact confirmed both by direct enzymatic
studies in which L-histidine inhibited both PDE and LPLD
activities and by the failure of ATX, in the presence of L-
histidine, to produce an inhibitor of LPA-stimulated
motility. Again, addition of Zn++ abrogated this inhibition
of enzyme activity. These data provide further evidence
that the LPLD activity of ATX, which results in the produc-
tion of the mediator LPA, is essential for ATX stimulation
of cellular motility.
The role of metal cations in the activation of ATX was fur-
ther investigated by first comparing the capacity of Ca++,
Mg++, Zn++ and Co++ to reverse the histidine-induced inhi-
bition of ATX enzymatic activities. Neither Ca++ nor Mg++
reversed the inhibitory effect of histidine, whereas Co++
alone stimulated a 50% increase in PDE and a 300%
increase in LPLD activities of ATX. Histidine partially
reversed both of these Co++-stimulated increases: PDE
activity was reduced to below uninhibited levels of prod-
uct while LPLD activity, though reduced by 50% com-
pared to treatment with Co++ alone, remained at levels
above untreated controls. The mechanism by which
cobalt activates ATX remains unexplained; however, Co++
has long been reported to replace one or more zinc cations
in a variety of zinc-bound metalloenzymes [21-23], some-
times with a notable increase in activity [24,25].
In contrast, Zn++ at concentrations as low as 0.25 mM
abrogated the inhibitory effects of 10 mM histidine upon
both the PDE and LPLD activities of ATX. This 40:1 ratio
of ligand to cation appears to be inconsistent with a sim-
ple stoichiometric coordination of the cation with the
metal-binding imidazole moiety. This would predict that
the maximum number of ligand groups to coordinate
with a Zn++ would be six. Our result is, therefore, difficult
to explain as simple chelation in solution between cations
and histidine. Perhaps, Zn++ acts upon ATX in a manner
that blocks the entry of histidine into the active site. For
example, Zn++ might coordinate with an electronically
available locus in proximity with the active site of ATX or
it might induce conformational changes in ATX that low-
ers the affinity of free histidine for the active site. Another
possibility is that Zn++ replaces another metal ion, result-
ing in a binding conformation with a lower affinity for L-
histidine. Interestingly, 0.25 mM Zn++ appeared to have a
slightly stimulatory effect upon ATX-induced motility, but
not LPA-induced motility. This suggests that Zn++ might
act in a way that stabilizes ATX in an active configuration.
Many members of the alkaline phosphatase superfamily
of metalloenzymes have Zn++ or Zn++ plus Mg++ incorpo-
rated into their catalytic site, although a number of other
metal requirements have been documented [14,26]. The
chelation agents, Na4-EDTA and 1,10-phenanthroline
both inactivate ATX, confirming that it is a metalloen-
zyme. Na4-EDTA complexes with a variety of cations,
including transition metals as well as alkali and alkaline
earth metals, and is thought to inactivate metalloenzymes
by removing the metal cation from its binding site. Under
the conditions of our assays, the IC50 of EDTA was ~5
mM. This inhibition was completely reversed by addition
of equimolar Zn++ and significantly reversed (about 75%
recovery) by addition of equimolar Ca++. In contrast, 1,
10-phenanthroline has more complicated and diverse
mechanisms of action. When utilized with metalloen-
zymes, it can form mixed complexes with the metal ions
as well as other cationic sites on the protein, resulting in
inactivation of the enzyme but not necessarily removal of
the metal cation [27]. Like histidine, 1,10-phenanthroline
requires less than equimolar concentrations of Zn++
(approximately 1:10) to reverse its inhibitory effect on
ATX. Based on all of our data with metal cations, it
appears that Zn++, Co++ and perhaps Ca++ can function as
the metal moiety in at least one of the two metal binding
sites [15] of the active metalloenzyme ATX, although we
do not know the predominant metal cations in the native
enzyme.
In order to determine what portion of the histidine mole-
cule was responsible for its inhibitory activity, we utilized
a number of commercially available histidine analogs.
These analogs were predominantly substituted on the
alpha carboxyl and alpha amino groups of histidine; but
they also included histamine, which lacks the alpha car-
boxyl group altogether, and imidazole, the weakly chelat-
ing ring that makes up the major portion of the histidine
side chain. Except for D-histidine, none of the other imi-
dazole-containing compounds were as inhibitory as L-his-
tidine. Among the 5 agents found to have significant
inhibitory activity, the relative potency is as follows: D-
histidine = L-histidine > histidine methyl ester >> N-
methyl histidine > histidinamide. Methylation of the
alpha amino group of histidine resulted in a stepwise loss
of potency, with a single methylation (N-methyl histi-
dine) resulting in about a 40% reduction in activity and a
double methylation (N, N-dimethyl histidine) not signif-
icantly different from untreated control reactions. Since
these two compounds should retain the positive charge
properties of the native alpha amino group, this could be
a steric effect. Similarly, change in the carboxyl group
(particularly amidylation or reduction) also decreased the
inhibitory potency, though that of esterified histidine
methyl ester was only slightly reduced. Interestingly, imi-
dazole itself, a moiety postulated to coordinate with the
cation at the active site of ATX, was not effective at the
tested concentrations. Likewise, amino acids, which
lacked imidazole on their side chains (e.g. glycine and L-Page 10 of 13
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functional groups of histidine are required for full inhibi-
tory activity: the alpha amino group, the alpha carboxyl
group, and the metal-binding imidazole side chain.
Recent work with Zn++-binding groups in matrix metallo-
proteinase inhibitors indicated that slight changes to the
Zn++-binding groups can result in major changes in effi-
cacy of inhibition [28], suggesting an approach for devel-
oping more potent, and perhaps highly specific,
pharmacologic inhibitors.
ATX, the major source of plasma LPA, has been implicated
in a number of physiological and disease-related proc-
esses [29], including tumor metastasis [30] and angiogen-
esis [31]. A pharmacologic agent that inhibits ATX activity
could have major therapeutic implications. Other than
the highly non-specific chelation agents [18], L-histidine
is the first reported inhibitor that acts on the LPLD activity
of ATX rather than acting on its downstream activation
cascade. This inhibition, requiring millimolar concentra-
tions of L-histidine, is reversible by Zn++ metal cations.
Our data suggest that the L-histidine-induced inhibition
of the ATX enzymatic activities is predominantly non-
competitive, i.e. Vmax is decreased significantly, while Km
is not significantly affected. Furthermore, the mechanism
of action of L-histidine does not appear to be simple stoi-
chiometric chelation of the metal cations within a metal-
loenzyme but is more likely a complex interaction with a
variety of moieties, including the metal cation, at or near
the active site. At concentrations required for an
inhibitory effect, most available histidine analogs resulted
in loss of cell viability. Free L-histidine, therefore, appears
to be unique in its ability to inhibit LPLD, and hence reg-
ulate a major source of LPA, in living systems. Since LPA
has significant pathological effects, the regulation of its
formation is of considerable interest. Potential problems
with L-histidine as a therapeutic agent include its lack of
potency and its conversion in vivo to histamine. While
there are known inhibitors of histidine decarboxylase,
such as the polyphenols of green tea [32], potent, stable,
and non-toxic analogs of histidine would appear to be
better therapeutic agents.
Conclusion
L-histidine inhibits the LPLD activity of ATX at millimolar
concentrations, reducing its capacity to produce its major
mediator, LPA.
Methods
Reagents
LPA (18:1) and S1P were purchased from Biomol
Research Laboratories, Inc. (Plymouth Meeting, PA). LPC
(18:1), SPC, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-
toluidine (TOOS), 4-aminoantipyrene (4-AAP), horserad-
ish peroxidase, choline oxidase, p-nitrophenyl-TMP, L-
histidine, D-histidine, imidazole, histamine, histidina-
mide, histidine methyl ester, N,N-dimethyl histidine,
histidinol, Na4-EDTA, and 1,10-phenanthroline were
from Sigma-Aldrich (St Louis, MO). N-methyl histidine
was from Bachem Bioscience (King of Prussia, PA).
Cell Lines
A2058 [33] and SKOV-3 cells were maintained in Dul-
becco's Modified Essential Medium (DMEM) supple-
mented by 2 mM glutamine, 1X penicillin/streptomycin
and 10% (v/v) heat-inactivated fetal bovine serum. SKOV-
3 cells (ATCC # HTB-77) were purchased from American
Type Culture Collection (Manassas, VA).
ATX Preparations
Highly purified recombinant human ATX (vATX), cloned
from an MDA-MB-435 cell library, was prepared from a
Vaccinia viral lysate, as described previously, through the
concanavalin A-agarose step [34].
In vitro Motility Assays
Cells were detached from their flasks with a brief exposure
to 0.05% trypsin and 0.02% versene and then resus-
pended at 2 × 106 cells/ml in DMEM supplemented with
1 mg/ml bovine serum album (DBA). Ten min before the
start of the assay, appropriate concentrations of potential
inhibitors were added to the different treatment groups.
Chemotaxis was assayed as described previously in detail
[35], utilizing gelatin-coated membranes for A2058 cells
and Type IV collagen-coated membranes for SKOV-3 cells.
Chemotaxis chambers were incubated 3 hr for A2058 cells
and 5 hr for SKOV-3 cells. Migrated cells were fixed and
stained, then quantified by cell counting under light
microscopy at 200X (SKOV-3 cells) or 400X (A2058 cells).
Enzymatic Activity Assays
Enzyme activities were determined using a modification
of the previously described assays [9]. Briefly, a 5 ml
aliquot of vATX (adjusted to give ≈ 6 pmoles vATX/reac-
tion) was incubated (50 µl reaction volume) with either 1
mM pNp-TMP or, alternatively, with 1 mM LPC, for 45
min at 37°C in DBA. DBA was utilized in order to mimic
the conditions of motility assays. For assays with histidine
and its analogues, stock solutions were prepared and
adjusted to physiological pH with NaHCO3 or HCl, as
appropriate. The inhibitor was added to the reaction mix-
ture; then, reactions were initiated by adding ATX.
For determination of 5'-nucleotide PDE activity, reactions
were stopped by the addition of 450 µl 0.1 N NaOH and
the nitrophenol product was detected by reading the
absorbance at 410 nm (A410 × 64 = nmoles). In order to
determine LPLD activity, released choline was detected as
follows: a 450 µl cocktail containing 50 mM Tris-HCl (pH
8), 5 mM CaCl2, 0.3 mM N-ethyl-N-(2-hydroxy-3-sulfo-Page 11 of 13
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(4-AAP), 5.3 U/ml horseradish peroxidase, and 2 U/ml
choline oxidase was added to the 50 µl reaction mixture
and incubated for 20 min at 37°C. Absorbance was read
at 555 nm and converted to nmoles of choline by compar-
ison to a choline standard curve (A555 × 17 = nmoles).
List of Abbreviations Used
ATX Autotaxin
DBA DMEM with 1% bovine serum albumin
DMEM Dulbecco's Modified Essential Medium
LPA Lysophosphatidic acid
LPC Lysophosphatidylcholine
LPLD Lysophospholipase D
NPP Nucleotide pyrophosphatase and phosphodiesterase
PDE Phosphodiesterase
pNp-TMP p-Nitrophenyl-TMP
S1P Sphingosine-1-phosphate
SPC Sphingosylphosphorylcholine
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